Medical device manufacturers supplying Great Britain will be able to continue using qualifying CE marking indefinitely after the government confirmed a long-term recognition policy intended to reduce duplicated regulatory approvals.
The Medicines and Healthcare products Regulatory Agency (MHRA) announced the decision on 21 October, following a consultation held between 16 February and 10 April 2026. More than 1,000 responses were received from patients, clinicians, manufacturers and other interested parties.
Medical devices span equipment such as pumps, implants and surgical instruments, as well as in vitro diagnostic products used to examine samples. Manufacturers seeking access to different markets must demonstrate compliance with the relevant requirements according to device type, risk and intended use.
After the UK’s departure from the European Union, a separate domestic conformity route raised the possibility that companies might eventually need additional approval for products already cleared for EU sale. Transitional rules allowed specified CE marked devices to remain available in Great Britain while the national system developed.
The new policy provides longer-term certainty by continuing recognition for qualifying EU-approved devices. That removes the prospect of a general expiry date for the recognised route, but it does not eliminate all regulatory requirements or mean any product bearing a label can enter the market without appropriate controls.
Manufacturers must still satisfy the applicable standards, maintain documentation and quality systems, and meet vigilance and post-market surveillance obligations. If a safety problem emerges, the MHRA retains responsibilities to protect patients and address products that do not meet the requirements.
The geographic scope also matters. The decision concerns Great Britain, while Northern Ireland operates under different medical device regulatory arrangements reflecting its relationship with EU law. Companies serving the whole UK therefore need to examine the requirements applicable to each market rather than assume a single identical process.
For producers, the commercial value lies in potentially avoiding additional tests, certificates or administrative processes where accepted approvals already exist. The saving will vary with the product portfolio, the approval route used and the manufacturer’s existing systems, and no universal reduction in compliance cost is guaranteed.
The decision may also help hospitals and distributors retain access to established devices that manufacturers might otherwise consider uneconomic to support through multiple regulatory routes. This is particularly relevant to products with relatively small markets or specialised clinical uses, for which extra certification costs can materially affect supply decisions.
Recognition does not mean the government has abandoned development of UK-specific rules. The MHRA intends to pursue further reforms of the domestic UKCA route, including pre-market regulation and possible future approaches to software and AI-enabled medical technologies. Those changes may affect how businesses choose among permitted compliance options.
Medical technology companies planning product launches must continue distinguishing between approval to place an item on the market and evidence that it will be purchased by hospitals or other customers. Procurement decisions, clinical needs, distribution arrangements and reimbursement structures remain separate commercial considerations.
As EU medical device requirements evolve, detailed guidance will remain important for certificates issued under differing regulatory frameworks. The 21 October decision establishes the enduring principle of recognition, while the legislation and regulatory instructions will determine its operation for specific classes of product.
The regulator’s consultation received more than 1,000 responses, reflecting the breadth of parties affected by device access rules. Manufacturers need predictable conformity arrangements, while healthcare providers depend on continuity of supply and patients need confidence in product safety. Maintaining recognised routes can address one source of disruption without resolving others, including production shortages, distribution problems or procurement delays. The MHRA must still monitor the safety of products once they are used, even where the initial conformity assessment took place under EU arrangements.
The result is a clearer long-term market access route, with ongoing responsibility for manufacturers and regulators to ensure that the devices supplied to patients remain safe and appropriately controlled.
You must be logged in to post a comment.